Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DuPont Merck licenses ImaRx (US) agent:

This article was originally published in Clinica

Executive Summary

ImaRx (US) has licensed its cardiovascular ultrasound contrast agent, MRX-115, to DuPont Merck. When ImaRx completes Phase II trials, due to start this month, DuPont Merck will assume responsibility for clinical development of the agent. In return for exclusive rights to MRX-115 for cardiology and radiology diagnostic applications in the Americas and cardiology applications in the EU, DuPont Merck will make up-front, milestone and royalty payments. ImaRx will retain rights to radiology applications in the EU and all rights in other regions.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094315

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel